Back
ESC Professional Premium Access

Inflammation in obesity-related HFpEF: the STEP-HFpEF programme

Session: Clinical trial updates on the GLP-1 receptor agonist, semaglutide
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Speaker: Professor S. Verma (Toronto, CA)
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
36 presentations
3 followers

7 more presentations in this session

Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access
Slides
Video
Like
Thumbnail

STEP-HFpEF Program Echocardiography Substudy

Speaker: Professor S. Solomon (Boston, US)

Access
Slides
Video
Like
Thumbnail

Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease

Speaker: Doctor R. Pratley (Orlando, US)

Access
Slides
Video
Like
Thumbnail

Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access
Slides
Video
Like
Thumbnail

Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial

Speaker: Professor S. Verma (Toronto, CA)

Access
Slides
Video
Like
Thumbnail

Access the full session

Clinical trial updates on the GLP-1 receptor agonist, semaglutide

Speakers: Professor S. Verma, Doctor M. Kosiborod, Professor S. Solomon, Doctor R. Pratley, Doctor M. Kosiborod...
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials

30 August 2024

ESC Premium Access

Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials

30 August 2024

ESC Premium Access

Epicardial adipose tissue: a modulator of atrial fibrillation?

31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novartis Explore sponsored resources